HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Bromotheophylline

HCID 11808
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
10381-75-6
Standard SMILES
Cn1c(=O)c2[nH]c(Br)nc2n(C)c1=O
InChIKey
SKTFQHRVFFOHTQ-UHFFFAOYSA-N
Molecular formula
C7H7BrN4O2
Average molar mass
259.06 g/mol
Monoisotopic mass
257.97524

Overview

Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome. Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.

Names & identifiers

Preferred name
Bromotheophylline
IUPAC
8-bromo-1,3-dimethyl-7H-purine-2,6-dione
English name
8-Bromotheophylline
Molecular formula
C7H7BrN4O2
Molecular weight
259.06

Names & synonyms

BromotheophyllineTheophylline, 8-bromo-1H-Purine-2,6-dione, 8-bromo-3,7-dihydro-1,3-dimethyl-UNII-FZG87K1MQ6FZG87K1MQ6EINECS 233-846-6NSC 164940NSC-1649408-BROMOTHEOPHYLLINE (USP-RS)8-BROMOTHEOPHYLLINE [USP-RS]RefChem:579298-Bromotheophylline
Show more names
Nsc164940AKOS NCG-0005LABOTEST-BB LT001345458-BROMOTHEOPHYLLINE 97%8-Bromotheophylline >8-Bromotheophylline ,97%
10381-75-68-Bromo-1,3-dimethyl-1H-purine-2,6(3H,9H)-dione8-bromo-1,3-dimethyl-7H-purine-2,6-dione8-bromo-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione8-Bromotheophyline8-bromo-1,3-dimethyl-3,9-dihydro-1H-purine-2,6-dione8-bromo-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dioneMFCD00022664

Database identifiers

CAS
10381-75-6
PubChem CID
11808
DTXSID
DTXSID7044768
ChEMBL
CHEMBL316160

Properties

Computed structural properties

XLogP
1
Topological polar surface area
69.3 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
3
Rotatable bonds
0
Heavy atoms
14
Formal charge
0
Complexity
297

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
SolubilitySoluble
Boiling PointDecomposes at 300 ºC
Melting Point295-316 ºC
Dissociation Constants5.45

Physicochemical properties

Melting point
295 · 295-297°C
Boiling point
469.5 · 469.5±55.0 °C(Predicted)
Density
1.862 · 1.862±0.06 g/cm3(Predicted)
storage temp.
Keep in dark place,Inert atmosphere,Room temperature
solubility
DMSO (Slightly), Methanol (Slightly, Heated)
pka
5.45 · pKa 5.45±0.1(H2O t=24) (Uncertain)
form
Solid
color

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Safety data

tsca
TSCA listed
ridadr
2811
hs_code
29395900
risk_code
20/21/22
Signal word
Warning
Symbol(GHS)
GHS07
safety_code
24/25-36/37
hazard_class
6.1(b)
packing_group
III
Hazard statements
H302-H315-H319-H335
Precautionary statements
P261-P264-P270-P271-P280-P301+P312+P330-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P362-P403+P233-P405-P501

Chemistry & industry

Pharmacology

Protein BindingThis pharmacokinetic property has not been determined.
Pharmacodynamics · 1 item

Bromotheophylline diuretic action will produce an immediate increase in urination frequency. This effect aids in the relief of bloating and menstrual pain. This diuretic function is performed by the an increase in glomerular filtration and a potential effect in the tubular reabsorption as it is established that the administration of these agents produce a rise in the urinary concentration of sodium a chloride and thus, an increase in their rates of excretion.

Mechanism of Action · 1 item

Bromotheophylline is part of the group of the xanthines. As part of this group, it is thought that bromotheophylline increases the permeability of the renal tubule, increases glomerular filtration rate and inhibits the sodium reabsorption in the proximal tubule. It is thought but not confirmed that pamabrom as a mixture seems to have an additional mechanism of action in which the presence of 2-amino-2-methyl-1-propanol produces the suppression of the antidiuretic hormone in the posterior pituitary gland.

Biological Half-LifeThe apparent elimination half-life is registered to be 21.35 hours.
Metabolism/MetabolitesThis pharmacokinetic property has not been determined.
Absorption, Distribution and Excretion · 4 items

When administered after one single oral dosage, bromotheophylline is rapidly absorbed and it reaches a maximal plasma concentration of 2.5 mg/L in 0.78 hours. The mean residence time is registered to be of 12 hours with an AUC in the first 8 hours of 27 mg.h/L.

This pharmacokinetic property has not been determined.

This pharmacokinetic property has not been determined.

This pharmacokinetic property has not been determined.

Uses & manufacturing

Related reactions

6 records
New reaction record
HRID 155909 reaction equation
HRID 155909As reactant
HRID 435107 reaction equation
HRID 435107As product
HRID 435108 reaction equation
HRID 435108As reactant
HRID 950317 reaction equation
HRID 950317As reactant
HRID 1721551 reaction equation
HRID 1721551As reactant
HRID 1727023 reaction equation
HRID 1727023As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
UNII
FZG87K1MQ6
EC Number
233-846-6
Nikkaji
J236.804H
White to Off-White
BRN
203069 · 203069
CAS DataBase Reference
10381 · 10381-75-6
FDA UNII
87 K1MQ6 · FZG87K1MQ6
EPA Substance Registry System
1 H-Purine-2,6-dione, · 1H-Purine-2,6-dione, 8-bromo-3,7-dihydro-1,3-dimethyl- (10381-75-6)
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335
Precautionary statements
261 · P261-P264-P270-P271-P280-P301+P312+P330-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P362-P403+P233-P405-P501
Risk Statements
20 · 20/21/22
Safety Statements
24 · 24/25-36/37
RIDADR
2811 · 2811
TSCA
TSCA listed
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
29395900 · 29395900
General Manufacturing Information1H-Purine-2,6-dione, 8-bromo-3,9-dihydro-1,3-dimethyl-: INACTIVE
Applications · 2 items

DescriptionBromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome. Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.

UsesThe active component in the diuretic Diurex.

Upstream & downstream products

Upstream raw materials

Acetic anhydrideTheophyllineHydrogen bromideNitric acidAcetic acid

Downstream products

8-Bromo-7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-2,6-purinedionePurino[8,7-b]quinazoline-2,4,6(1H,3H,11H)-trione, 1,3-dimethyl- (9CI)8-anilino-1,3-dimethyl-7H-purine-2,6-dione8-Bromo-7-(3-chloropropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione